Detailed, indexed protocol and historical site performance data are two of the most valuable assets in clinical research. Separately, each tells part of the story. Together, they form the foundation for more predictable, better-executed trials.
The challenge? These data sets are too often siloed, owned by different teams, segregated by different architecture, and consulted at different points in the planning process. That disconnect makes the information appear less than powerful. But just connect the battery and the motor to see real movement.
Why Protocol Data and Outcomes Data Are Stronger Together
Protocol data captures the “what” of a trial: eligibility criteria, objective to endpoint structures, assessment requirements, visit schedules, and procedural burden. Historical site performance and outcomes data capture the “what happened”: enrollment velocity, dropout rates, protocol deviation patterns, amendment history, and site-level execution quality.
When study teams analyze these two data sets together, a more complete picture emerges. Protocol features can be evaluated not just on idealized projections, but on operational realities. A visit-heavy schedule, for example, may look manageable on paper. Historical outcomes data from similar trials can reveal whether that schedule has consistently driven participant dropout or triggered protocol amendments at comparable sites.
Pitfalls Study Teams Should Watch Out For
Understanding where silos create risks to success is the first step toward eliminating them. The most common pitfalls include:
- Designing protocols in a vacuum. When protocol teams don’t have access to historical outcomes data, complexity tends to creep in. Since Phase III trials now average 3.5 substantial amendments, up from 2.3 a decade ago, the operational consequences of over-engineered protocols are substantial.
- Relying on relationships over performance data for site selection. Familiarity with a site doesn’t guarantee fit for a specific protocol. Without historical performance benchmarks, teams risk placing trials at sites that lack the capacity, participant population, or experience to execute a particular protocol’s demands successfully.
- Forecasting enrollment without protocol context. Enrollment projections that don’t account for protocol-specific burden, such as frequent visits or restrictive eligibility criteria, often diverge sharply from actual performance.
- Catching burden too late. Participant and site burden that isn’t quantified during design becomes visible only after enrollment slows or deviations accumulate. At that point, corrections are expensive and time-consuming.
Keys to Success: Connecting Protocol and Outcomes Data
Study teams that connect protocol and outcomes data early in the planning process gain a meaningful operational advantage. Here’s how to approach it:
Start the conversation at protocol design. Feasibility shouldn’t wait until the protocol is finalized. Bringing historical outcomes data into early design reviews allows teams to evaluate how choices around visit frequency, eligibility criteria, and assessment burden have played out in comparable trials.
Quantify burden before first patient in. Qualitative assessments of burden aren’t enough. Teams need structured, data-driven scoring that models participant and site experience, linking specific protocol elements to projected dropout rates, deviation risk, and enrollment velocity.
Ground site selection in multi-dimensional evidence. The most effective site selection processes combine historical performance data, protocol fit, competitive landscape, and site capabilities. Relying on any single dimension narrows the picture.
Align operational teams around shared data. Feasibility, clinical operations, and data teams often work from different information sets. Establishing a shared data foundation creates consistent decision-making across functions and reduces the risk of misaligned expectations.
Treat forecast accuracy as a design input. When enrollment projections are built using protocol features and site-level historical data, they reflect operational reality rather than optimistic assumptions. That accuracy protects timelines and budget from the start.
Frequently Asked Questions
Protocol data refers to the design specifications of a trial, including eligibility criteria, visit schedules, endpoints, and procedural requirements. Outcomes data refers to what actually happened during trial execution, including enrollment rates, dropout rates, protocol deviations, amendment frequency, and site-level performance. Both data types are essential and integrating them enables study teams to evaluate design choices through an operational lens before a trial begins.
When protocol and outcomes data are siloed, study teams make design and site selection decisions without the full context of how similar choices have performed historically. This leads to inaccurate enrollment forecasts, underestimated participant and site burden, and reactive amendments rather than proactive design.
Historical site performance data reveals how individual sites and principal investigators have executed in comparable studies, including enrollment velocity, deviation rates, and capacity during overlapping trials. When combined with protocol-specific burden scoring and competitive landscape analysis, this data helps teams select sites that are genuinely positioned to perform well on this specific study, rather than relying solely on prior relationships, generic, average site scores, or regional familiarity.
Integration should begin at the protocol design phase, before eligibility criteria and visit schedules are finalized. Early access to historical outcomes data allows teams to identify design elements that have consistently driven amendments, participant burden, or enrollment delays in similar trials. Addressing these risks at the design stage is significantly less costly than correcting them during execution.
Predict Trial Performance Before It Becomes Trial Risk
The path from siloed data to integrated foresight doesn’t require substantial human resource investment and extensively re-built architecture. It requires access to the right data assets and the analytical tools to connect them.
WCG Trial IntelX™, powered by the ClinSphere™ platform, draws on more than 80,000 complete protocols and 44,000 benchmarked trials to surface exactly these kinds of correlations. By connecting design choices to real-world outcomes at scale, study teams gain the foresight to make informed decisions before those decisions become costly problems.
Trial IntelX was built specifically for bringing together protocol data, site performance benchmarks, and outcomes history to help study teams design feasible trials, select well-matched sites and know what support they need, and forecast timelines with confidence. The platform transforms trial planning from reactive management to predictive decision-making, before a single participant is enrolled.
Ready to see what your trial could look like before it starts? Learn how to make sure your study is feasible and ready by getting in touch with one of our experts using the form below.
Study Ready Feasibility Services
Draw on our unmatched data to anticipate where plans may break down, enable smarter choices earlier, and set trials up for success in reality, not just on paper.